RTP’s AskBio acquires gene expression firm

 In Daily Digest

Share this story:

RTP’s AskBio, a clinical stage and gene therapy company, has acquired Edinburg’s Synpromics,  a gene control, expression and technology firm. Both bioscience companies focus on AAV gene therapy, which uses harmless viruses as a vector to insert DNA into chromosomes as a means of treating rare and often incurable diseases such as hemophilia, muscular dystrophy and late-stage heart failure. Formed in 2001 to advance the work of Dr. Richard Jude Samulski, former director of the Gene Therapy Center at the UNC, AskBio’s acquisition will allow for increased efficiency and safety of gene therapy vectors. Terms of the deal were not disclosed, but Synpromics will operate as a subsidiary and remain headquartered in the United Kingdom

Recent Posts
Contact Us

Questions or feedback? Drop us a message!

Start typing and press Enter to search